Lunaphore is a pioneer in advanced tissue analysis for cancer diagnostic. Around 20 million cases of cancer are diagnosed worldwide each year. This number is expected to increase by 70% in 2030. Laboratories need to increase rapidity and accuracy to provide fast and reliable diagnostics.
Lunaphore develops an automated tissue analytic machine specialized in tumorous cell detection. The key innovation lies in Lunaphore’s application of a unique microfluidic technology: Fast Fluidic Exchange (FFeX).
Beyond rapidity, this allows the same tissue sample to be used for several microfluidic tests.
The technology produces results that correlate more accurately with real biomarker amounts compared to conventional methods for identifying breast, lung, prostate and colon cancers.
It also performs assays much faster than standard techniques due to short incubation times.
CEO: Ata Tuna Ciftlik
Headquarters: Lausanne, Switzerland
Initial investment date: August 2017
Site: lunaphore.ch
Cancer is one of the most burdensome diseases in the world, requiring constant support and innovation from the industry. With LUNAPHORE’s dedicated focus on immuno-oncology research applications, its FFeX technology has great potential for wider application.
FOLLOW ALPANA NEWS:
SWITZERLAND
Tour de l’Ile 1
CH – 1204 Geneva
+41 22 312 20 50
SILICON VALLEY, USA
Via Regina
Saratoga CA 95070
+1 408 644 8104
Copyright 2021 by ALPANA VENTURES